(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/126600 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61K 47/59* (2017.01)
A61K 47/64 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2019/084180

(22) International Filing Date:
09 December 2019 (09.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2022283	21 December 2018 (21.12.2018)	NL
2023468	10 July 2019 (10.07.2019)	NL
2023568	25 July 2019 (25.07.2019)	NL

(71) Applicants: **SAPREME TECHNOLOGIES B.V.** [NL/NL]; Professor Bronkhorstlaan 10 G 92, 3723 MB Bilthoven (NL). **CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN** [DE/DE]; Charité-platz 1, 10117 Berlin (DE).

(72) Inventors: **POSTEL, Ruben**; Yalelaan 62, LSI, Room 2.09, 3584 CM Utrecht (NL). **FUCHS, Hendrik**; Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie Charité - Universitätsmedizin, Berlin Campus, Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin (DE).

(74) Agent: **NEDERLANDSCH OCTROOIBUREAU**; P.O. Box 29720, 2502 LS The Hague (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW

(57) Abstract: The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to a composition or therapeutic combination comprising an antibody-drug conjugate or antibody-oligonucleotide conjugate and the first proteinaceous molecule of the invention. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament. The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.

WO 2020/126600 A1